使用合成氨酸替代品控制血管生成
J Folkman1, P B Weisz, M M Joullié
1Department of Surgery, Harvard Medical School, Boston, MA 02115.
Science (New York, N.Y.)
|March 17, 1989
概括
研究人员发现了一种强大的血管新生抑制剂,beta-cyclodextrin tetradecasulfate,它与类固醇协同作用. 与肝素相比,这种化合物显示出显著增强的抗血管效应,为由血管生长驱动的疾病提供潜在的治疗益处.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 血管生物学 血管生物学
背景情况:
- 持续的毛细血管血管生长是许多疾病的特征,包括癌症.
- 血管新生,新血管的形成,对于瘤生长至关重要.
- 开发安全有效的血管生成抑制剂对于治疗应用至关重要.
研究的目的:
- 为了确定有效的血管生成抑制剂.
- 探索化合物对血管生成的协同作用.
- 评估血管生成依赖疾病的潜在治疗剂.
主要方法:
- 研究了氨酸和类固醇的协同作用的抗血管效应.
- 测试了beta-cyclodextrin tetradecasulfate作为一种与类固醇结合的肝素替代品.
- 使用胚胎生物测试和子角膜新血管化模型.
主要成果:
- 与类固醇结合的β-cyclopodextrin tetradecasulfate在胚胎中显示出比肝素的100至1000倍更大的抗血管生成效果.
- 这种组合疗法在子角膜新血管化模型中增强了类固醇的抗血管性作用.
- 循环寡糖体显示出作为一种强大的血管新生抑制剂的显著潜力.
结论:
- 当与类固醇一起使用时,β-cyclodextrin tetradecasulfate是一种高度有效的血管生成抑制剂.
- 这种化合物代表了控制病态血管生成的有希望的治疗候选者.
- 对这种协同作用组合的进一步研究可能会导致各种疾病的新治疗方法.
相关概念视频
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...